Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Biologic therapy. Chemotherapy. Edinburgh Cancer Research Center, Edinburgh, Scotland, United Kingdom



Survival: 17.3 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United Kingdom
   
City/State/Province: Edinburgh, Scotland
   
Hospital: Edinburgh Cancer Research Center
   
Journal: Link
   
Date: 8/2010

Description:
Patients
This phase 3 study involved women with advanced breast cancer. Patients were separated into two treatment groups. Group A consisted of 207 women with a median age of 54 years and a range of 26-80. Group B included 201 women with a median age of 51 years and a range of 28-83.

Treatment
Patients in group A were given a combination of the chemotherapy agent capecitabine and the biologic therapy lapatinib, which is a tyrosine kinase inhibitor.

Patients in group B were given capecitabine alone.

Toxicities
In group A, four deaths were related to adverse effects including cardiorespiratory arrest, lymphedema (lymphatic obstruction causing fluid retention), and hyponatremia (electrolyte imbalance). Other serious adverse events reported for this group included diarrhea, dehydration, vomiting, and shortness of breath.

Six deaths related to treatment were reported for group B. Causes included diarrhea, vomiting, respiratory arrest, pulmonary embolism, and cardiac arrest. Other serious adverse events reported for this group included diarrhea, dehydration, vomiting, and nausea.

Results
Median overall survival in group A (lapatinib + capecitabine) was 17.3 months.

Group B (capecitabine alone) had a median overall survival of 14.9 months.

Support
This study was funded by GlaxoSmithKline, makers of Tykerb (also known as Tyverb), the brand name for lapatinib.

Correspondence Dr. David Cameron; email: d.cameron@ed.ac.uk

E-mail to a Friend Email Physician More Information